Top in GI: Updates on acute hepatitis outbreak; Crohn’s disease remission
Click Here to Manage Email Alerts
During the International Liver Congress, experts provided updates on the growing outbreak of acute, severe hepatitis of unknown etiology in children.
As of June 20, both new and retrospectively identified cases were reported in 33 countries, according to Philippa Easterbrook, MD, senior scientist at the Global HIV, Hepatitis and STI Programs at WHO headquarters in Geneva. It was the top story in gastroenterology last week.
Another top story was about remission rates among patients with Crohn’s disease who received treatment with ustekinumab or adalimumab, which researchers said were “surprisingly high.”
Read these and more top stories in gastroenterology below:
Acute hepatitis outbreak swells to nearly 900 cases; global data shows ‘mixed picture’
An outbreak of acute, severe hepatitis of unknown etiology in children has grown to 894 cases across 33 countries, according to data presented during a media briefing at the International Liver Congress. Read more.
‘Surprisingly high’ remission rates for both ustekinumab, adalimumab in Crohn’s patients
Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according to results of the SEAVUE study in The Lancet. Read more.
WHO: HCV elimination by 2030 demands ‘scale-up, simplification’ of care pathways
WHO presented updated guidance on hepatitis C, calling for drastic simplification of care pathways to alleviate access gaps in HCV testing and treatment, during a joint WHO-EASL-CDC symposium at the International Liver Congress. Read more.
AGA proposes first pharmacologic treatment plan for patients with IBS-C, IBS-D
The American Gastroenterological Association has issued clinical guidelines that outline a pharmacologic treatment plan for patients with irritable bowel syndrome and its subtypes, IBS-constipation and IBS-diarrhea. Read more.
Antiviral combination plus standard therapy achieves ‘controlled biological state’ in HBV
Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced HBsAg levels over 24 weeks compared with standard therapy, according to a presenter at the International Liver Congress. Read more.